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Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for 
infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is also 
increased, emphasising the importance of protecting patients by vaccination. Available data in patients with multiple 
myeloma suggest a suboptimal anti-SARS-CoV-2 immune response, meaning a proportion of patients are unprotected. 
Factors associated with poor response are uncontrolled disease, immunosuppression, concomitant therapy, more lines 
of therapy, and CD38 antibody-directed and B-cell maturation antigen-directed therapy. These facts suggest that 
monitoring the immune response to vaccination in patients with multiple myeloma might provide guidance for clinical 
management, such as administration of additional doses of the same or another vaccine, or even temporary treatment 
discontinuation, if possible. In those who do not exhibit a good response, prophylactic treatment with neutralising 
monoclonal antibody cocktails might be considered. In patients deficient of a SARS-CoV-2 immune response, adherence 
to measures for infection risk reduction is particularly recommended. This consensus was generated by members of 
the European Multiple Myeloma Network and some external experts. The panel members convened in virtual meetings 
and conducted an extensive literature research and evaluated recently published data and work presented at meetings, 
as well as findings from their own studies. The outcome of the discussions on establishing consensus recommendations 
for COVID-19 vaccination in patients with multiple myeloma was condensed into this Review.
Introduction 
Patients with multiple myeloma have a substantially 
increased risk for bacterial and viral infection, and a two-fold 
increased risk for infection has been reported in patients 
with monoclonal gammopathy of unknown significance.1,2 
In a survey, 167 (52%) of 322 patients with multiple 
myeloma reported at least one infectious period in the year 
before starting anti-myeloma therapy and 133 (43%) of 314 
patients reported at least one infectious period in the first 
6 months after the start of anti-myeloma therapy.3
Multiple myeloma itself can lead to severe  immuno-
suppression by impairing practically all immune effector 
mechanisms, including B cells, T cells, natural killer cells, 
dendritic cells, and the complement system, thereby 
increasing the risk for infections even before the start of 
multiple myeloma therapy. Most multiple myeloma drugs, 
including proteasome inhibitors, dexamethasone, high-
dose melphalan, monoclonal anti-CD38 antibodies, bi-
specific T-cell engagers, and cellular therapies (eg, chimeric 
antigen receptor T-cell therapy) result in specific and 
cumulative immune suppression. Immune impairment 
might be further aggravated by myeloma-related or 
treatment-associated organ dysfunction, comorbidities, 
and, frequently, by the immune senescence associated 
with older age,4 as well as by T-cell exhaustion after long-
standing therapy.5
Risk of SARS-CoV-2 infection and mortality in 
multiple myeloma
The first cluster of people with pneumonia with a novel 
coronavirus as suspected pathogen was reported in 
December, 2019.6 Since this period, patients with multiple 
myeloma and other monoclonal gammopathies are at 
greater risk for SARS-CoV-2 infection, but precise data of 
the increase are not available as yet and  depend on patient 
and treatment related factors as well as on the situation of 
the disease. Patients infected with SARS-CoV-2 more 
often have a prolonged course of infections and are at 
an increased risk of mortality.7 The largest series reported 
by the International Myeloma Society included 
650 hospitalised patients with plasma cell disorders 
(table 1). Their median age was 69 years and 617 (95%) of 
the 650 patients presented with multiple myeloma, with 
331 (54%) of these 617 patients receiving first-line therapy.7 
Of those patients, 203 (33%) died, with substantial 
variability of mortality reported for individual countries, 
ranging from 27% to 57%. Risk factors for mortality were 
age, International Staging System stage 3 disease, high-
risk cytogenetics, renal impairment, active or progressive 
disease, and one or more comorbidities. Importantly, 
specific therapies, such as autologous haematopoietic 
stem-cell transplantation (HSCT), or other treatments 
were not associated with adverse outcome. The Spanish 
Multiple Myeloma Cooperative group reported the 
outcome of 167 patients with multiple myeloma and 
COVID-19 disease (table 1).8 In-hospital mortality of 
patients with multiple myeloma was higher (56 patients; 
34%) compared with age-matched and sex-matched 
patients without cancer (38 patients; 23%). Independent 
risk factors for mortality were age, male sex, active or 
progressive disease, and renal impairment. A 2020 meta-
analysis on outcome of patients with SARS-CoV-2 
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infection and haematological malignancies revealed a 
mortality rate of 33% (95% CI 25–41) in the subgroup of 
412 patients with plasma cell disorders.13 This study 
included mainly hospitalised patients reported by 
individual groups (table 1).7,8,9–12 Generally, a higher risk of 
mortality was noted in the non-White patient population 
and in those aged 60 years or older.
SARS-CoV-2 vaccines 
Presently, several vaccines are available in high-income 
countries and other vaccines are approved in other 
regions of the word; several additional vaccines will 
probably be approved soon (table 2). The vaccines aim for 
inducing immunity against the receptor-binding domain 
of the spike protein, or the full-length spike protein, 
nucleocapsid protein, or other viral epitopes. The vaccines 
using mRNA or DNA technology provide the genetic 
code for the respective peptide antigens and pack the 
genetic information either in lipid nanoparticles or 
liposomes (tozinameran [BNT162b2], elasomeran 
[mRNA-1273], and others), or use adenoviruses as vectors 
(ChAdOx1 nCoV-19, or Ad26.COV2-S, and others). Other 
vaccines use attenuated or inactivated SARS-CoV-2 virus 
(CoronaVac and BBIBP-CorV), or recombinant subunit 
protein (NVX-CoV2373 and ZF2001), or vesicular 
stomatitis virus (IIBR-100 and V590) or lentivirus 
(Covid-19/aAPC) as vector, or modified dendritic cells 
with lentivirus vectors (LV-SMENP-DC). The efficacy of 
the vaccines presently available in the high-income 
countries has been evaluated in randomised trials 
including 23 848–43 448 individuals. All the vaccines 
protect the majority of vaccinated people (72–95%) against 
mild-to-moderate COVID-19 disease, and even more 
(86–100%) are protected against severe COVID-19 disease 
and mortality. For almost all vaccines, two doses 
administered 3–12 weeks apart are recommended, 
although for the Ad26.COV2.S vaccine only one dose is 
required. Recently, a third dose (a second one for Ad26.
COV2.S vaccine) has been recommended for patients 
with immunossupression by the Centers for Disease 
Control and Prevention.22 WHO maintains a working 
document that provides updated information and 
includes most vaccines in development, which is available 
at the WHO website.
Immune response to vaccination against 
COVID-19 in the general population 
Current information on the magnitude and type of the 
immune response required to protect against infection or 
severe disease is insufficient. Studies in rhesus macaques 
show that neutralising antibodies—and not CD4+ and 
CD8+ T-cell responses—correlate with median viral loads 
in bronchoalveolar lavage and nasal mucosa23 and, in 
patients infected with COVID-19, receptor-binding domain 
antibodies were shown to correlate with neutralising 
antibodies as well as disease severity and predicted 
survival.24 Studies in healthy controls showed substantial 
antibody responses to mRNA-127325 and ChAdOx1 
nCoV-19,26 and antibody and cellular immunity against 
BNT162b2.27 IgG antibody responses occurred as early as 
9–12 days after the first dose and peaked after the second 
dose in individuals who were COVID-19-naive, but 
antibody concentrations were significantly higher at all 
assessed time points in a sub-cohort of individuals with 
pre-existing immunity against SARS-CoV-2.28 A recent 
study showed high antibody activity in healthy people 
against the spike protein receptor-binding domain, with 
nearly all enrolled individuals showing activity in the virus 
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Mortality rate Risk factors for mortality [OR (95% CI); p value]
Age High-risk 
cytogenetics






617 69 years 
(34–92 years)












167 71 years 
(62–78 years)












58 67 years (IQR 
12·5 years)










100 68 years 
(41–91 years)
·· 22% 1·8 (0·7–4·7; 
p=0·26)




75 73 years 
(47–88 years)
28 months Newly diagnosed multiple 
myeloma: 54·8%; relapsed or 
refractory multiple 
myeloma: 50%
·· ·· ·· ·· ··
Engelhardt and 
colleagues12
21 59 years 
(46–83 years)
20 months 0% ·· ·· ·· ·· ··
OR=odds ratio. *Hypertension.
Table 1: Studies on outcome of mainly hospitalised patients with COVID-19 and multiple myeloma
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neutralisation assay and in the more sensitive live-virus 
focus reduction neutralisation mNEeonGreen test.29 
Antibody concentrations were age dependent (with the 
highest concentrations reported in the cohort aged 
18–55 years and the lowest concentrations reported in 
those aged 71 years or older) and persisted with a notable 
decline over 6 months after the second dose of the 
mRNA-1237 vaccine. Antibodies induced by BNT126b2 in 
healthy individuals protect against variants with the D614G 
substitution and the alpha (B.1.1.7) variant, whereas the 
neutralisation of the beta (B.1.351) variant is five-fold 
reduced.30 Individuals vaccinated with either BNT126b2 or 
ChAdOx1 nCoV-19 showed three-fold to five-fold lower 
neutralisation titres against the delta variant (B.1.617.2) 
compared with the alpha variant.31 A study showed vaccine 
effectiveness was 93·7% and 88·0% for the alpha and delta 
variant with the BNT126b2 vaccine and 74·5% and 67·0% 
with ChAdOx1 nCoV-19.32 Despite this reduction in 
effectiveness, vaccinated individuals seemed to be largely 
protected against severe disease and hospitalisation.
Interesting data have also been reported on the 
cellular immune response. The BTN161b2 vaccine has 
been shown to induce a de novo S1-specific and 
S2-specific response in CD4+ cells and CD8+ T cells with 
reactivity against eight spike epitopes, with most 
of them being conserved on the mutant strains.27 
A preprint33 has reported robust T-cell responses to the 
wild-type spike and nucleocapsid proteins in healthy 
individuals vaccinated with either BNT162b2 or 
mRNA-1273. This study also reported detectable, but 
diminished, T-cell responses to spike variants (alpha, 
beta, and B.1.1.248).
Immune response to non-SARS-CoV-2 vaccines 
in patients with multiple myeloma 
Previous studies showed reduced antibody responses 
against several vaccines (eg, pneumococci, staphylococcal 
alpha toxin, tetanus, diphtheria toxoids, influenza, 
and other vaccines) in patients with multiple myeloma 
and significantly lower antibody concentrations were 
also observed in patients with monoclonal gammopathy 
of unknown significance.34 The reduced vaccination 
response is a consequence of the myeloma-induced and 
treatment-induced immune suppression, but is also 
affected by comorbidities and older age. Older age has 
been shown to be associated with impaired ability to 
mount a strong vaccine response because of reduced 
CD8+ T-cell effector responses, reduced CD4+ T-cell 
functionally, and poor memory cell maintenance.35
Immune response to SARS-CoV-2 infection and 
to vaccines in patients with multiple myeloma 
Terpos and colleagues36 studied the neutralising antibody 
response 22 days after the first dose of the BNT162b2 
vaccine in 48 older (median age 83 years) patients with 
multiple myeloma versus a control group of similar age. 
Of the 48 patients, 35 (73%) were receiving anti-multiple 
myeloma therapy, four (8·3%) were in remission without 
any therapy, and nine (18·8%) had smouldering multiple 
myeloma. Patients had significantly lower neutralising 
antibody titres compared with the control group 
(20·6% vs 32·5%; p<0·01) and neutralising antibody 
titres above 30% (positivity cutoff) were noted in only 
12 (25%) of 48 patients with multiple myeloma compared 
with 57 (55%) of 104 controls. A clinically relevant virus 
Department of Hematology, 
CHU de Liège, Liège, Belgium 
(Prof J Caers MD); 
Universitätsklinikum 
Hamburg–Eppendorf II, 
Medizinische Klinik und 
Poliklinik, Hamburg, Germany 
(Prof K Weisel MD); Northern 
Centre for Cancer Care, 
Freeman Hospital, Newcastle 
Upon Tyne Hospitals trust, 
Newcastle Upon Tyne, UK 
(Prof G Jackson MD); Sorbonne 
Université-INSERM, 
UMR-S 938, Centre de 
Recherche Saint-Antoine-Team 
Hematopoietic and leukemic 
development, Assistance 
Publique-Hôpitaux de Paris, 
Hôpital Pitié Salpetrière, 
Département d’Hématologie et 
de Thérapie Cellulaire, Paris, 
France (L Garderet MD); CHU 
Poitiers, Poitiers, France 
(Prof X Leleu MD); Inserm, 
Poitiers, France (Prof X Leleu); 
University Hospital Heidelberg, 
Internal Medicine V and 
National Center for Tumor 
Diseases (NCT), Heidelberg, 
Germany 
(Prof H Goldschmidt MD); 
Department of Hematology, 
Ankara University, Ankara, 
Turkey (Prof M Beksac MD); 
First Department of Medicine, 
Center for Oncology, 
Hematology, and Palliative 
Care, Clinic Ottakring, Vienna, 
Austria (M Schreder MD, 
N Zojer MD); Hematology 
Research Unit, Department of 
Hematology, Odense 
University Hospital, and 
Department of Clinical 
Research, University of 
Southern Denmark, Odense, 
Denmark 
(Prof N Abildgaard MD); 
Department of 
Hematooncology, University 
Hospital Ostrava and Faculty of 
Medicine, University of 
Ostrava, Ostrava, Czech 
Republic (Prof R Hajek MD); Oslo 
Myeloma Center, Oslo 
University Hospital Oslo, 
Norway (F Schjesvold MD); KG 
Jebsen Center for B Cell 
Malignancies, University of 
Oslo, Oslo,  Norway 
(Prof M Boccadoro MD); 
European Myeloma Network 
(EMN) Italy, Torino, Italy 
(Prof M Boccadoro)
Manufacturer Vaccine type Dosage Overall efficacy Current approvals*
mRNA-1273 Moderna (USA) mRNA Two doses 28 days apart 94·1% 14 days after second dose14 The USA, Europe, and the UK
BNT162b2 Pfizer–BioNTech 
(USA)
mRNA Two doses 21 days apart 52% after one dose; 94·6% 7 days 
after the second dose15
The USA, Europe, and the UK
Ad26.COV2.S Johnson & Johnson 
(USA)
Viral vector One dose Vaccine efficacy against COVID-19 
is 66·1%; vaccine efficacy against 
severe COVID-19 is 85·4% (at 
28 days)16





Viral vector Two doses 28 days apart 
(intervals of >12 weeks 
studied)
Overall vaccine efficacy is 70·4% at 
14 days or more after second dose17
WHO and COVAX, the UK, 
Europe, the USA, India, and 
Mexico









Viral vector Two doses (first, rAd26; 
second, rAd5) 21 days 
apart
91·6% at 21 days after first dose 
(day of dose two)19
Russia, Belarus, Argentina, 
Serbia, UAE, Algeria, Palestine, 
and Egypt
CoronaVac Sinovac Biontech 
(China)
Inactivated virus Two doses 14 days apart 83·5% at 14 days or more after 
dose two20
China, Brazil, Columbia, 
Bolivia, Chile, Uruguay, Turkey, 
Indonesia, and Azerbaijan
BBIBP-CorV Sinopharm 1/2 
(China)
Inactivated virus Two doses 21 days apart 78·1% or more after dose two21 China, UAE, Bahrain, Serbia, 
Peru, and Zimbabwe
UAE=United Arab Emirates. *As of May 31, 2021.
Table 2: Vaccines approved in the high-income countries and selected vaccines of global relevance
4 www.thelancet.com/haematology   Published online October 28, 2021   https://doi.org/10.1016/S2352-3026(21)00278-7
Review
inhibition was observed in 4 (8%) of the 48 patients with 
multiple myeloma and 21 (20%) of the 104 individuals in 
the control group. All four patients with clinically 
relevant neutralising antibodies were in remission 
(three with a very good partial response, and one with a 
partial response) without any anti-multiple myeloma 
therapy and all of them had normal concentrations of 
uninvolved immunoglobulins. Similarly, only one of the 
nine patients with smouldering multiple myeloma 
had neutralising antibody titres above 30%. The patient 
with a positive response had normal concentrations 
of uninvolved immunoglobulins, whereas all eight 
non-responders had immunoparesis. In a follow-up 
study,37 the authors noted neutralising antibody titres of 
50% or more only in 158 (57%) of the 276 patients 
with plasma cell neoplasms (213 with symptomatic 
multiple myeloma, 38 with smouldering multiple 
myeloma, and 25 with monoclonal gammopathy of 
unknown sig nificance) with a median age of 74 years 
versus 183 (81%) of 226 controls matched for age and sex 
(p<0·001) on day 50 after vaccination with BNT162b2 or 
7 weeks after the first dose of ChAdOx1 nCoV-19. Only 
114 (54%) of 213 patients with multiple myeloma and 
23 (61%) of 38 patients with smouldering multiple 
myeloma had clinically relevant antibody concentrations 
(p=0·013). Patients with monoclonal gammopathy of 
unknown significance had a similar frequency of high 
antibody concentrations (84%) to individuals in the 
control group. When antibody concentrations were 
already assessed on day 20 after the first vaccination, a 
lower positivity rate was noted but with a similar 
ratio of response rates between patients with 
multiple myeloma, smouldering multiple myeloma, and 
monoclonal gammopathy of unknown significance. 
Antibody responses did not differ on day 22 between 
patients immunised with either one of the vaccines. 
Univariate analysis showed a higher risk for inadequate 
antibody response in patients with multiple myeloma, 
smouldering multiple myeloma, lymphopenia, low non-
clonal IgA concentrations, and therapy with belantamab 
mafodotin and with anti-CD38-based therapies, whereas 
in female individuals, a lower risk was noted.
A UK group studied IgG anti-spike protein antibodies 
in 93 patients with multiple myeloma (median age 
65 years [range 47–87 years] in antibody-positive group 
and median age 70 years [47–87 years] in antibody-
negative group) after one dose of either BNT162b2 or 
ChAdOx1 nCoV-19.38 After a median follow up of 33 days 
(range 21–61 days), antibodies were reported in 52 (56% 
[95% CI 46–66]) of the 93 patients, with no significant 
difference between both vaccines. Seven (8%) of the 
93 patients already had pre-existing antibodies before 
vaccination due to previous PCR-proven or highly 
suspected clinical COVID-19 infection. Excluding these 
patients would still amount to a positive result in 
45 (52%) of 86 patients. Factors associated with an 
antibody response were depth of response to multiple 
myeloma therapy (complete response or very good partial 
response), no immunoparesis at the time of vaccination, 
and fewer previous lines of therapy. Having treatment 
was associated with a lower response, but no specific 
therapy was associated with low response rates compared 
with other treatments. Nine (82%) of the 11 patients 
vaccinated within 12 months of autologous HSCT had 
tested positive for SARS-CoV-2 IgG antibodies. The 
authors then did a total antibody assay (which also 
measures IgM and IgA antibody response) in 40 IgG 
non-responders and observed a positive result in 13 (33%) 
of the 40 patients without detectable IgG antibodies. The 
authors also put their findings into perspective by 
comparing them with results of their hospital staff, 
which revealed a positive response in 175 (99%) of 
177 tested individuals. A study from Italy reported a 
significantly reduced IgG response to spike protein 
subunits S1 and S2 in 42 patients with multiple myeloma 
(median age 73 years; range 47–78 years) receiving 
concomitant multiple myeloma therapy after the first 
and second dose of the BNT162b2 vaccine versus 
controls.39 The geometric mean concentration of 
antibodies in patients with multiple myeloma was 
7·5 AU/mL 3 weeks after the first dose and 106·7 AU/mL 
2 weeks after the second dose, compared with 17·1 AU/mL 
(p<0·001) and 353·3 AU/mL (p=0·003), respectively, in 
an older control population (median age 81 years; range 
79–87 years).39 The authors defined a cutoff of 15 AU/mL 
as a positive response. According to this definition, the 
proportion of responders increased from 9 (21%) of the 
42 individuals from week 3 after the first dose to 33 (79%) 
of the 42 individuals 2 weeks after the second dose in the 
multiple myeloma cohort, compared with 19 (53%) of the 
36 individuals and all 36 (100%) of the individuals, 
respectively, in the control population (p<0·001). A 
univariate analysis of factors associated with response 
showed poor antibody response in patients receiving 
single-agent daratumumab or combination therapy 
which was not noted patients with proteasome inhibitor 
or immunomodulatory drug-based treatment, or with 
combinations thereof.
Researchers from New York, USA, reported highly 
variable SARS-CoV-2 IgG antibody concentrations 
in 320 patients with multiple myeloma vaccinated with 
either BNT162b2 or mRNA-1273, with antibody concen-
trations varying between 5 AU/mL and 7882 AU/mL, 
but their median concentration (149 AU/mL) was 
significantly lower compared with the value obtained in 
a small control cohort of 67 health-care workers 
(median 300 AU/mL, range 21–3335 AU/mL; p<0·0001, 
Mann-Whitney U test).40 Patients with previous 
COVID-19 infection before full vaccination had ten 
times higher antibody concentrations compared with 
patients who were COVID-19-naive. Repeated antibody 
measurements from baseline to 60 days after full 
vaccination showed delayed suboptimal responses, and 
41 (15·8%) of 260 patients with multiple myeloma did 
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not mount detectable IgG anti-SARS-CoV-2 antibodies. 
Patients receiving active multiple myeloma treatment 
had significantly lower antibody concentrations, as well 
as those with more than three previous lines of therapy, 
grade 3 lymphopenia, and those receiving anti-CD38 
therapy or B-cell maturation antigen-targeted therapy 
(70 AU/mL on active therapy vs 183 AU/mL without 
active therapy; p=0.004, Mann-Whitney U test). Another 
study from Italy assessed the IgG anti-SARS-CoV-2 
response in patients with haematological malignancies, 
including 44 patients with multiple myeloma. Of these, 
33 (75%) mounted an antibody response.41 On the basis 
of the findings of the two studies,40,41 the authors 
underscored the need for routine serological screening 
to assess responses to vaccination in patients with 
haematological malignancies, including multiple 
myeloma.
Clearance of SARS-CoV-2 virus and risk of 
reinfections 
Prolonged COVID-19 disease and SARS-CoV-2 virus 
shedding has also been observed in patients with multiple 
myeloma (Terpos E, unpublished), which provides an 
optimal milieu for the evolution of virus mutations 
in an immunosuppressed host. Even in otherwise healthy 
people, SARS-CoV-2 virus can persist for some time, as 
has been shown in a recent study, which reported 
persistence of viral RNA 3 months after resolution of 
symptoms in five (5%) of 93 study participants.42 All 
five individuals had similar antibody concentrations 
to the PCR-negative group, but had increased CD8+ T-cell 
responses. Patients with multiple myeloma and vaccine-
induced or previous SARS-CoV-2 infection-induced 
immunity might lose immune protection due to 
progression or reoccurrence of active disease or 
specific anti-multiple myeloma therapies, and might 
again become particularly vulnerable to SARS-CoV-2 
reinfection.
Current effectiveness of vaccines against the 
different SARS-CoV-2 variants
All presently available mRNA, vector-based, or protein 
subunit vaccines show high activity against severe 
symptomatic infection by the original viral strain and 
reduce mortality by more than 95%. Mutations of the 
30 000-base RNA genome of the SARS-CoV-2 virus occur 
at a rate of around two single letter mutations per month, 
which is roughly half as fast the rate of influenza, and a 
quarter of the rate of HIV.43 Most of the SARS-CoV-2 
mutations are harmless, and might even weaken the 
virus, but some of them give the virus an advantage over 
the other versions. Several variants of concern or of 
interest have been identified (table 3). All of these 
variants carry mutations in the receptor-binding domain 
that enhance their receptor binding affinity, leading to 
higher transmissibility. The delta variant has rapidly 
become the most dominant out of all of the existing 
variants, including the alpha variant, which was 
predominant before. The delta variant harbours 
mutations within the N-terminal domain of the 
receptor-binding domain of the spike protein,31 which 
renders the variant 60% more transmissible than the 
original virus, and triggers surges in cases and deaths 
around the world. In-vitro studies showed that, 
compared with the alpha variant, a three-fold reduction 
of the neutralising activity against the delta variant and 
a 16-fold reduction against the beta variant occurred 
after two doses of the BNT126b2 vaccine.31 Similarly, 
after two doses of ChAdOx1 nCoV-19, a six-fold reduction 
in neutralising activity against the delta variant and a 
nine-fold reduction in neutralising activity against the 
beta variant was noted compared with the alpha 
variant;31 findings, which accord with another study 
showing lower neutralisation activity against the delta 
variant after vaccination with mRNA-1237 or with 
BNT126b2,46 and a recent study in the UK showed 
slightly reduced effectiveness of the BNT126b2 and 
ChAdOx1 nCoV-19  vaccine against the delta variant.32 
Vaccination-induced and convalescent sera exert only 
minimally lower neutralisation activity against the alpha 
variant compared with the original variant, but alpha 
variants that acquire an E484K mutation showed a 
six-fold decreased sensitivity to immune sera from 
individuals vaccinated with BNT126b2.47 Reports 
associate the delta variant with higher transmissibility, 
virulence, and greater disease severity and case fatality 
rates.48 Substantially increased transmissibility, a three-
fold reduction in binding, and a 3·5-fold reduction 
in neutralising antibodies has also been reported for 
the beta variant in individuals vaccinated with the 
mRNA-1273 vaccine.49 The vaccine still provided 
protection against any documented infection, with an 
effectiveness of 75·0% and of 97·4% against severe 
disease.50 Low concentrations of neutralising antibodies 
(against live virus and pseudovirus; for example, a 
chimeric vesicular stomatitis virus that expresses the 
SARS-CoV-2 spike protein) of the beta variant have been 
reported in young (aged 30 years; range 24–40 years) 
South African participants who were HIV-negative and 
vaccinated with the ChAdOx1 nCoV-19 vaccine. Notably, 
vaccine efficacy regarding mild-to-moderate disease 
against this variant was only 10·8%. Severe cases were 
not observed in the placebo or in the vaccinated group.51 
Recent results with the Ad26.COV2.S vaccine showed 
five-fold and 3·3-fold reduced neutralising antibody 
titres against the alpha variant and gamma variant, 
respectively, but functional non-neutralising antibodies 
and T-cell responses were largely preserved.52 The 
protein-based NVX-CoV2373 vaccine showed 86% efficacy 
against the alpha variant, but only 60% against the beta 
variant.53,54 For the gamma variant, a 4·8-fold reduction in 
neutralisation activity for people vaccinated with the 
mRNA-1273 vaccine, and 3·8-fold reduction for the 
BNT126b2 vaccine were shown.55 Despite the reduction 
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in neutralising activity of vaccine-induced antibodies, the 
sera were still able to neutralise the kappa (B.1.617.1) 
variant, suggesting that those vaccines provide 
sufficient protective immunity. Additionally, all SARS-
CoV-2 vaccines tested so far also induce non-neutralising 
antibody-dependent cytotoxicity and spike-specific CD4+ 
and CD8+ T cells, which also serve as immune effectors,56 
supporting their clinical effectiveness even against the 
newer, more transmissible variants.
Options for patients with poor antibody 
response
Patients with no or suboptimal immune responses might 
require additional doses of the same vaccine or a different 
vaccine, a strategy supported by the UK Joint Committee 
On Vaccination.57 Preliminary data suggest high 
immunogenicity of an a priori heterologous prime-boost 
vaccination.58 Whether other approaches, such as the use 
of other vaccines (eg, adjuvanted59 or self-replicating 
RNA vaccines60), will lead to the desired increase in 
SARS-CoV-2 specific humoral and cellular immunity 
remains unclear. Some manufacturers are adapting their 
mRNA vaccines to better match the variants of concern, 
particularly the delta variant. Other vaccines of interest 
include those which use specific virus proteins, 
inactivated whole virus, adjuvanted vaccines, or self-
amplifying mRNA vaccines that enable the production of 
more antigen. Different modes of vaccine administration 
(eg, oral or intranasal) should facilitate more frequent 
dosing and induce secretory IgA antibody responses. 
However, it remains unclear whether these options will 
elicit the desired protection in patients with a poor 
response due to disease-inherent immune deficiency or 
immune suppressive therapy. Immunsuppression 
induced by myeloma can only be improved by effective 
anti-myeloma therapy inducing a deep response. 
Immunsuppression due to anti-myeloma therapy can 
only be overcome by discontinuation of this therapy and, 
in particular, discontinuation of prolonged anti-CD38 
therapy. Daratumumab therapy reduces polyclonal 
plasma cells and concentrations of polyclonal 
immunoglobulins of almost all isotypes,61 and 
First detection, 
Country
Notable mutations Evidence of clinical changes Protected by
Transmissibility Virulence Antigenicity
Alpha (B.1.1.7*) September, 2020, UK N501Y, 69–70del, 





 61% (42–82%) more 
lethal44
Reduced antigenic activity (ECDC); 
in the 484K variants: six-fold 
decrease of immune sera (mRNA 
vaccines) and 11-fold decrease in 






Beta (B.1.351†) December, 2020, 
South Africa




No evidence of increased 
virulence
Reduced neutralisation by 
antibodies (ECDC)
BNT162b2 (Pfizer–BioNTech) and 
mRNA-1273 (Moderna) might be 
two-thirds less effective (serum 
neutralising antibodies); ChAdOx1 
nCoV-19 (Oxford–AstraZeneca) is 
effective only in 10% of cases; 
Ad26COV2.S (Janssen) has 89% 
efficacy; and NVX-CoV2373 (Novavax) 
has 60% efficacy
Gamma (P.1†) January, 2021, Brazil 
and Japan





45%) more lethal 
(CADDE)
Overall reduction in effective 
neutralisation (ECDC)
Possible reduction of vaccine efficacy 
(ECDC)
Eta (B.1.525*) December, 2020, 
Nigeria and the UK
E484K and F888L Likely increased 
(CDC)
Likely increased (CDC) Modestly reduced neutralisation 
(COG-UK)




May, 2020, USA; July, 
2020, USA




Increased (CDC) 4·0–6·7-fold and two-fold decrease 
in neutralisation titres from 
convalescent patients and vaccine 
recipients (CDC); CoronaVac 
equally effective45
No data available yet
Iota (B.1.526*; 
B.1.526.1*)
November, 2020, USA E484K,1 D614G, A701, 
L5F,1 T95I, D253, 
S477N,1 D80G, ∆144, 






Reduced neutralisation by 
convalescent and post-vaccination 
sera, reduced susceptibility to 
monoclonal antibody cocktail of 
bamlanivimab and etesevimab
No data available yet




Under investigation Reduction in effective 
neutralisation
No major impairment of efficacy of 
vaccines used in India reported




Under investigation Reduction in effective 
neutralisation
No major impairment of efficacy of 
vaccines used in India reported
CADDE=Centre for adenovirus, discovery, detection, genomics & epidemiology. CDC=Center for Disease Control and Prevention. COG-UK=COVID-19 Genomics UK Consortium. ECDC=European Center for Disease 
Prevention and Control. NERVTAG=New and Emerging Respiratory Virus Threats Advisory Group. *Variants of interest. †Variants of concern. 
Table 3: Virus mutations of concern and of recent interest
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daratumumab maintenance therapy has been associated 
with an increased risk of COVID-19 infection.62 
Hence, discontinuing anti-CD38 antibody therapy might 
increase the chance of a vaccine-induced anti-SARS-CoV-2 
response. However, this consideration probably applies 
to similar immuno suppressive treatments, such as bi-
specific T-cell engagers, antibody–drug conjugates, 
chimeric antigen receptor T-cell therapy, aggressive 
combination therapies, and others. By contrast, 
lenalidomide maintenance therapy, should not decrease 
the response to SARS-CoV-2 vaccination because it has 
been shown to enhance T-cell immunity and the response 
to a pneumococcal seven-valent conjugate vaccine63 and 
to a hepatitis C DNA vaccine.64 Nevertheless, the most 
promising approach is probably the vaccination of 
patients after a deep sustained response to multiple 
myeloma therapy during a treatment-free period.
For patients not vaccinated and for those with no or 
insufficient response to vaccination against COVID-19, 
long-term prophylaxis with monoclonal antibodies with 
specificity against spike proteins might be a valuable 
option, particularly after exposure to an infected 
individual and during phases of uncontrolled disease 
and need for aggressive therapy.65 One infusion of the 
neutralising monoclonal anti-SARS-CoV-2 antibody 
bamlanivimab reduced the incidence of COVID-19 
infection by 57%, from 15·2% to 8·5%, and completely 
prevented mortality in 483 residents and staff in skilled 
nursing and assisted-living facilities compared with 
482  individuals receiving placebo only.66 A recent trial 
aiming to prevent COVID-19 disease after exposure to a 
person with SARS-CoV-2 infection with subcutaneous 
administration of 1200 mg of REGEN-COV, a cockatil 
consisting of two monoclonal antibodies against the 
spike protein (casirivimab and imdevimab) revealed 
significant efficacy.67 Symptomatic infection developed 
in only 11 (2%) of 753 participants of the active 
treatment, but in 59 (8%) of the 752 participants of the 
placebo group. This treatment has already received 
emergence use authorisation by the US Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMA). This antibody cocktail also significantly reduced 
hospitalisation or death in 2696 COVID-19-infected 
outpatients by 71·3% (p<0·001).68 Only eight (1·3%) of 
1355 of the study participants receiving the experimental 
therapy were admitted as inpatients or died, compared 
with 62 (4·6%) of 1341 of those randomly assigned to 
the placebo group. Furthermore, this monoclonal 
antibody cocktail resolved symptoms and reduced 
SARS-CoV-2 viral load more rapidly than placebo. 
Another monoclonal antibody cocktail consisting of 
bamlanivimab plus etesevimab has received emergency 
use authorisation by the US FDA for post-exposure 
prophylaxis for individuals who are at high risk of 
acquiring SARS-CoV-2 infection and for treatment of 
patients with mild-to-moderate COVID-19 infection 
and at high risk of progressing to severe disease.69 
 Convalescent plasma or plasma products could be 
another option for post-exposure or general prophylaxis. 
This treatment prevented severe COVID-19 disease 
in older adults (median age 76·4 ± 8·7 years) with 
mild COVID-19 symptoms70 and led to rapid SARS-
CoV-2 clearance in SARS-CoV-2-infected patients who 
were immuno compromised and receiving anti-CD20 
therapy.71 However, in patients with severe COVID-19 
disease, no benefit could be shown.72 Apart from these 
options, the search for active treatments against 
COVID-19 infections has gained substantial momentum; 
more than 560 trials with investigational anti-COVID-19 
drugs are currently listed on Clinical Trials.gov.
Vaccine hesitancy 
The poor compliance with recommendations for 
vaccination with COVID-19 vaccines is a major challenge 
for society given that a vaccination acceptance of greater 
than 80% seems to be required for herd immunity. 
A large survey identified low knowledge, low income, 
and negative attitudes of social contacts, safety concerns, 
and religious beliefs, as hurdles for their willingness 
to get vaccinated.73 By contrast, confidence in the 
importance of vaccines rather than in their safety or 
effectiveness was shown to be the strongest determinant 
for vaccine uptake in a large retrospective analysis.74 
A survey in Canadian school teachers showed that those 
with an educational background in science or 
engineering, a higher general knowledge of vaccines, 
and belief that COVID-19 was a serious illness, were 
more likely to intend to receive a COVID-19 vaccine.75 
We noted a high willingness of patients with multiple 
myeloma (279 [83%] of 335 patients) to receive COVID-19 
vaccines, which is higher compared with the general 
population, possibly due to greater awareness that these 
patients probably have about the risks of SARS-CoV-2 
infection,3 more frequent contact with health-care 
personnel, and greater interest in medical developments.
Safety 
Table 4 shows the side-effects listed in the Summary of 
Product Characteristics of the vaccines approved by the 
EMA and US FDA for emergency use; with the exception 
of the BINT162b2 vaccine (Comirnaty, Pfizer-BioNTech), 
which is fully approved by the US FDA. Side-effects after 
vaccination are reported by approximately two-thirds of 
vaccinated individuals. Most of the side-effects are 
observed with all common vaccines. Localised injection-
site symptoms, such as pain, swelling, and erythema, 
occur within 24–48 h after vaccination and resolve 
spontaneously within days after vaccination.28,76 Other 
common side-effects are muscle pain, fever, and joint 
pain. Vaccine recipients with pre-existing immunity have 
a higher frequency of common side-effects than those 
without pre-existing immunity—an observation that also 
applies to individuals who receive their second vaccine 
dose,77 with the exception of ChAdOx1 nCoV-19  vaccine, 
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which is typically better tolerated after the second 
administration.78 Headaches and fatigue seem to be more 
common in women than in men, and more common in 
individuals younger than 55 years.77 In a few patients, 
delayed localised cutaneous reactions have been reported 
2–12 days after receiving the mRNA-1273 vaccine.79 These 
reactions were described as pruritic, painful, and 
oedematous pink plaques. Skin biopsy showed a mild 
predominantly perivascular mixed infiltrate with 
lymphocytes and eosinophils, consistent with a dermal 
hypersensitivity reaction. After the second dose, a similar 
localised injection-site reaction developed, often sooner 
than with the first-dose reaction.
Severe allergic reactions have been reported with a 
frequency of 1:100 000 for the BNT162b2 vaccine, which 
is higher than the rate reported for non-COVID-19 
vaccines (1:1 000 000).76 The allergenic component is most 
likely the polyethylenglycol excipient, which is also used 
in the mRNA-1273 and the NVX-CoV2373 vaccines. In 
the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines, 
polysorbate 80 is used for embedding the viral vector, and 
could elicit allergic reactions in individuals sensitive to 
these compounds. Polysorbate 80 and polyethylenglycol 
are structurally related, and skin testing has shown cross-
reactive hypersensitivity.80 Anaphylactic reactions occur 
within a few minutes after injection and usually respond 
well to epinephrine injection. The US and European 
contraindications for BNT126b2 and mRNA-1273 
vaccines differ in respect to the intensity of previous 
allergic episodes. In the USA, an anaphylactic reaction to 
a dose of one of the vaccines is considered as 
contraindication for a further dose; however, in Europe, a 
severe allergic reaction is considered as contraindication 
for a further dose. A similar discrepancy concerns the 
ChAdOx1 nCoV-19 vaccine. In the USA, patients with 
known hypersensitivity should not be re-exposed to this 
vaccine, whereas in Europe individuals allergic to the 
vaccine or any ingredient should not be re-exposed to the 
vaccine. Both adenovirus-vectored vaccines (ChAdOx1 
nCoV-19 and Ad26.COV2.S) confer a potential risk of an 
unusual form of thrombotic complications manifesting 
predominantly as cerebral venous sinus thrombosis, but 
also in the form of splanchnic, portal vein, and hepatic 
vein thrombosis. High concentrations of D-dimers and 
low concentrations of fibrinogen are common, and 
suggest the activation of coagulation.81 The occurrence of 
this vaccine-induced thrombotic thrombocytopenia 
(VITT) syndrome has initially been noted predominantly 
in women, but recent reports show no sex preponderance. 
Most affected people are younger than 60 years, but this 
syndrome has also been diagnosed in older patients. The 
underlying mechanisms have been delineated to the 
induction of auto antibodies against platelet factor 4 
causing thrombotic thrombo cythemia.82 This syndrome 
has been termed vaccine-induced thrombotic thrombo-
cytopenia, and its pathogenesis is not entirely clear. One 
theory includes the possibility that components of the 
vaccine bind to platelet factor 4 and generate a neoantigen, 
which induces an immune response. The antibody 
formation might be stimulated by inflammatory signals. 
A few days later, antibodies against platelet factor 4  arise, 
leading to activation of platelets and other cell types and, 
finally, to thrombosis often in atypical sites. In case this 
complication is suspected, testing for antibodies against 
platelet factor 4 should be ordered, and treatment with a 
non-heparin anticoagulant, high-dose glucocorticoids, 
and high-dose intravenous immunoglobulins should be 
initiated.83 In June, 2021, new safety information was 
published by the EMA and by the Centers for Disease 
Control and Prevention: myocarditis and pericarditis has 
been observed after vaccination with BTN126b2 and also 
after administration of the mRNA-1273 vaccine. This 
BNT162b2 (Pfizer-BioNTech) mRNA-1273 (Moderna) ChAdOx1 nCoV-19 (Oxford–AstraZeneca) Ad26COV2.S (Janssen)
Very common 
(more than 1 in 10)
Injection site pain and swelling, 
tiredness, headache, muscle 
pain, joint pain, chills, fever
Swelling in the underarm, headache, 
nausea vomiting, muscle ache, joint 
aches, and stiffness, injection site 
pain or swelling, feeling very tired, 
chills, fever
Injection site tenderness, pain, warmth, itching, 
or bruising, feeling tired (fatigue) or generally 
feeling unwell, chills or feeling feverish, 
headache, feeling sick (nausea), joint pain or 
muscle ache
Headache, nausea, muscle aches, injection site 
pain, feeling very tired
Common 
(up to 1 in 10)
Injection site redness, nausea Rash, rash, redness, or hives at the 
injection site
Injection site swelling or redness, fever (>38°C), 
being sick (vomiting) or diarrhea
Injection site redness and swelling, chills, joint 
pain, cough, fever
Uncommon 
(up to 1 in 100)
Enlarged lymph nodes, feeling 
unwell, pain in limb, insomnia, 
injection site itching
Injection site itchiness Sleepiness or feeling dizzy, decreased appetite, 
enlarged lymph nodes, excessive sweating, itchy 
skin, or rash
Rash, muscle weakness, arm or leg pain, feeling 
weak, feeling generally unwell, sneezing, sore 
throat, back pain, tremor, excessive sweating
Rare 
(up to 1 in 1000)
Temporary one-sided facial 
drooping (Bell’s palsy)
Temporary one-sided facial 
drooping (Bell’s palsy)
·· Allergic reaction, hives
Very rare 
(up to 1 in 10 000)
·· ·· Blood clots often in unusual locations (eg, brain, 
liver, bowel, spleen) in combination with low 
concentrations of blood platelets
Blood clots often in unusual locations (eg, 
brain, liver, bowel, spleen) in combination 
with low concentrations of blood platelets
Not known Severe allergic reaction Severe allergic reactions 
(anaphylaxis), hypersensitivity
Severe allergic reactions (anaphylaxis), 
hypersensitivity
Severe allergic reaction
Table 4: Adverse events and frequency thereof as listed in the Summary of Product Characteristics by the US Food and Drug Administration and the European Medicines Agency for the 
different COVID-19 vaccines 
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side-effect is primarily observed in young male adults. 
Another recently reported adverse event is Guillain-Barre 
syndrome, which has been associated with the ChAdOx1 
nCoV-19 and the BNT162b2 vaccine.84,85 Furthermore, 
patients with previous capillary leak syndrome should 
not be vaccinated with Ad26.COV2.S.86 An update of the 
incidence and possible management recommendations 
can be found on the pharmacovigilance pages of the 
EMA (EudraVigilance) website, and on the US FDA’s 
Adverse Event Reporting System (FAERS) Public 
Dashboard.
Recommendations for clinical practice 
All patients with monoclonal gammopathy of unknown 
significance, smouldering multiple myeloma, multiple 
myeloma, and monoclonal gammopathies of clinical 
significance should be vaccinated with a COVID-19 
vaccine, and this recommendation applies to their family 
members as well. Whenever possible, patients should be 
vaccinated during phases of well controlled disease 
and without concomitant anti-myeloma therapy. 
The International Myeloma Society87 recommends to 
vaccinate patients scheduled for stem-cell preparation 
shortly before the procedure and to vaccinate patients 
after autologous HSCT after a recovery period of 
3 months or more (panel). Limited data show suboptimal 
or no response in patients with poorly controlled multiple 
myeloma with or without concomitant anti-myeloma 
therapy. Nevertheless, vaccination should be considered 
in those patients on the basis of individual judgement, 
but stimulation of a protective immune response is less 
likely. Protective antibody responses are less likely in 
older patients, in those with uncontrolled disease, 
lymphopenia, immunoparesis, and in those with more 
than one previous treatment line. Furthermore, specific 
multiple myeloma treatments, such as autologous HSCT, 
anti-CD-38 antibodies, anti-B cell maturation antigen 
therapies (including bi-specific T-cell engagers and 
chimeric antigen receptor T-cell therapy) impair immune 
reactivity, and often contribute to low vaccination 
response. Evaluation of the humoral and cellular 
immune response obtained after vaccination is presently 
not recommended by the Centers for Disease Control 
and Prevention45 and several other organisations, but 
might be helpful for identifying patients with 
immunosuppression in order to recom mend a third 
vaccine dose, as recently approved by the US FDA.88 The 
main concern of these organisations is the absence of a 
generally accepted validated test system, and scarce data 
on the threshold of antibody titres that confer protection 
from infection or disease. Also, there is little information 
on the interplay between humoral and cellular immune 
responses and their role in protection. With the new 
approval of an additional (third) vaccine dose for patients 
who are immunosuppressed, the question arises how to 
define immunosuppression? Thus, clinicians are faced 
with a dilemma, which in clinical practice will cause 
them to assess the immune response to vaccination for 
patient selection for an additional dose, even in full 
knowledge that they are basing their decision on a still 
imperfect methodology. In patients who contract or have 
been exposed to COVID-19, administration of protective 
neutralising monoclonal antibodies might be considered, 
and one preparation consisting of casirivimab–
imdevimab (REGEN-COV [Regeneron; Tarrytown, NY, 
USA] or Ronaprever [Roche; Basel, Switzerland]) has 
already been approved in many countries for exposure 
prophylaxis for patients with high risk for severe 
COVID-19, hospitalisation, and mortality.89 Another 
monoclonal antibody cocktail consisting of bamlanivimab 
and etesevimab has received emergency authorisation in 
For more on pharmacovigilance 
see https://bit.ly/30KmNJ7
For the US Food and Drug 
Administration’s Adverse 
Event Reporting System 
(FAERS) Public Dashboard see 
https://open.fda.gov/data/faers/
Panel: Summary of recommendations from the European Myeloma Network for 
vaccination against SARS-CoV-2
The European Myeloma Network recommends that all patients with monoclonal 
gammopathy of unknown significance, smouldering multiple myeloma, multiple 
myeloma, and monoclonal gammopathies of clinical significance should be vaccinated 
with a COVID vaccine
Patients should be vaccinated preferably
• Before onset of active multiple myeloma
• During well controlled disease at times of minimal residual disease negativity, 
complete response, or very good partial response
• Before start of therapy, before stem-cell collection, and more than 3 months after 
autologous haematopoietic stem-cell transplantation
• During periods without therapy (exception: lenalidomide maintenance therapy)
• Vaccination might be considered on individual judgment in patients with poorly 
controlled disease or ongoing therapy, but induction of protective immune response 
is less likely
• Patients with previously confirmed COVID-19 infection should be vaccinated as well 
(one dose might be sufficient)
Consider risk factors for poor response
• Uncontrolled disease
• Immunoparesis
• Number of previous lines of therapy
• Age, certain treatments (eg, anti-CD38 antibodies and B cell maturation antigen-
targeted therapy, including bi-specific T-cell engagers and chimeric antigen receptor 
T-cell therapy)
Routine evaluation of the immune response to vaccination is not supported by the 
Centers for Disease Control and Prevention and other organisations but allows 
identification of patients without any or with low anti-SARS-CoV-2 immune response
In case of immune impairment
• Administer a third vaccine dose
• Insufficiently protected patients should comply with principles for infection risk 
reduction
• Those patients will depend on herd immunity and will benefit from so-called ring 
vaccination of partners and close social contacts
• Administration of protective monoclonal antibodies might be considered in 
immunosuppressed patients who contract or have been exposed to COVID-19
• Health-care personnel caring for patients with multiple myeloma and household 
members should be vaccinated
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the USA for the same indication.90 Convalescent plasma 
could also be considered for prophylaxis as it had been 
shown to reduce progression of mildly symptomatic 
COVID-19 disease in older patients,70 but has as yet not 
been evaluated for post exposure or general prophylaxis. 
Active anti-SARS-CoV-2 antivirals are in development for 
prophylaxis or for after contact exposure. Notably, the 
first representative of an anti-SARS-CoV-2 drug is the 
nucleoside analogue molnupiravir, which has been 
submitted to the US FDA for emergency authorisation. 
Patients with immunosuppression need to be advised to 
adhere to recommendations for infection risk reduction 
issued by the Centers for Disease Control and 
Prevention—namely, social distancing, mask wearing, 
handwashing, cleaning and disinfecting surfaces which 
are frequently touched, and daily health monitoring. 
These patients might end up depending on the creation 
of herd immunity and on a strategy of so-called ring 
vaccination, including vaccinating all household 
members, close social contacts, and care givers.
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